首页> 外文期刊>Pharmacological reviews >Pituitary adenylate cyclase-activating polypeptide and its receptors: from structure to functions.
【24h】

Pituitary adenylate cyclase-activating polypeptide and its receptors: from structure to functions.

机译:垂体腺苷酸环化酶激活多肽及其受体:从结构到功能。

获取原文
           

摘要

Pituitary adenylate cyclase-activating polypeptide (PACAP) is a 38-amino acid peptide that was first isolated from ovine hypothalamic extracts on the basis of its ability to stimulate cAMP formation in anterior pituitary cells. PACAP belongs to the vasoactive intestinal polypeptide (VIP)-glucagon-growth hormone releasing factor-secretin superfamily. The sequence of PACAP has been remarkably well conserved during the evolution from protochordate to mammals, suggesting that PACAP is involved in the regulation of important biological functions. PACAP is widely distributed in the brain and peripheral organs, notably in the endocrine pancreas, gonads, and respiratory and urogenital tracts. Characterization of the PACAP precursor has revealed the existence of a PACAP-related peptide whose activity remains unknown. Two types of PACAP binding sites have been characterized. Type I binding sites exhibit a high affinity for PACAP and a much lower affinity for VIP whereas type II binding sites have similar affinity for PACAP and VIP. Molecular cloning of PACAP receptors has shown the existence of three distinct receptor subtypes, the PACAP-specific PAC1 receptor, which is coupled to several transduction systems, and the two PACAP/VIP-indifferent VPAC1 and VPAC2 receptors, which are primarily coupled to adenylyl cyclase. PAC1 receptors are particularly abundant in the brain and pituitary and adrenal glands whereas VPAC receptors are expressed mainly in the lung, liver, and testis. The wide distribution of PACAP and PACAP receptors has led to an explosion of studies aimed at determining the pharmacological effects and biological functions of the peptide. This report reviews the current knowledge concerning the multiple actions of PACAP in the central nervous system and in various peripheral organs including the endocrine glands, the airways, and the cardiovascular and immune systems, as well as the different effects of PACAP on a number of tumor cell types.
机译:垂体腺苷酸环化酶激活多肽(PACAP)是一种38个氨基酸的肽,首先根据其刺激下垂体cAMP形成的能力从羊下丘脑提取物中分离得到。 PACAP属于血管活性肠多肽(VIP)-胰高血糖素-生长激素释放因子-分泌素超家族。从原虫到哺乳动物的进化过程中,PACAP的序列已经非常保守,这表明PACAP参与了重要生物学功能的调控。 PACAP广泛分布于脑和周围器官,尤其是内分泌胰腺,性腺以及呼吸道和泌尿生殖道。 PACAP前体的表征揭示了其活性仍然未知的PACAP相关肽的存在。已经表征了两种类型的PACAP结合位点。 I型结合位点对PACAP表现出高亲和力,而对VIP的亲和力低得多,而II型结合位点对PACAP和VIP表现出相似的亲和力。 PACAP受体的分子克隆表明存在三种不同的受体亚型,与几种转导系统偶联的PACAP特异性PAC1受体,和主要与腺苷酸环化酶偶联的两种PACAP / VIP无关的VPAC1和VPAC2受体。 PAC1受体在脑,垂体和肾上腺特别丰富,而VPAC受体主要在肺,肝和睾丸中表达。 PACAP和PACAP受体的广泛分布导致了旨在确定该肽的药理作用和生物学功能的大量研究。本报告回顾了有关PACAP在中枢神经系统和包括内分泌腺,气道,心血管和免疫系统在内的各种外围器官中的多种作用的当前知识,以及PACAP对多种肿瘤的不同作用单元格类型。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号